ArticleJournal of cancer research and clinical oncology2014
Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- The Interdependence of Carbon Substrates and Metabolic Pathways Enables the Metabolic Plasticity of Cancer Cells.Advances in experimental medicine and biology · 2026Review
- ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.British journal of cancer · 2025Article
- Lipidomics by Nuclear Magnetic Resonance Spectroscopy and Liquid Chromatography-High-Resolution Mass Spectrometry in Osteosarcoma: A Pilot Study.Metabolites · 2024Article
- Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets.Frontiers in oncology · 2022Review
- Cancer-testis antigen lactate dehydrogenase C4 as a novel biomarker of male infertility and cancer.Frontiers in oncology · 2022Review
- Evaluating a Panel of Autoantibodies Against Tumor-Associated Antigens in Human Osteosarcoma.Frontiers in genetics · 2022Article
- Metabolomics in Bone Research.Metabolites · 2021Review
- Revisiting lactate dynamics in cancer-a metabolic expertise or an alternative attempt to survive?Journal of molecular medicine (Berlin, Germany) · 2020Review
- Targeting Nuclear NADCancers · 2020Article
- Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.Journal of clinical laboratory analysis · 2020Article
- Insights in Osteosarcoma by Proton Nuclear Magnetic Resonance Serum Metabonomics.Frontiers in oncology · 2020Article
- Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders.Advances in experimental medicine and biology · 2020Review
- Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.Cancer science · 2018Article
- Histone Demethylase JARID1B Is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression via Demethylation of H3K27me3.Oncology research · 2018Article
- Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.Cancer medicine · 2017Article
- Application of metabolomics in sarcoma: From biomarkers to therapeutic targets.Critical reviews in oncology/hematology · 2017Review
- Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.Journal of the American Society for Mass Spectrometry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. However, few biomarkers of diagnostic significance have been established. In recent years, high-throughput transcriptomic and metabolomic approaches make it possible for studying the levels of thousands of biomarkers simultaneously.
methodsIn this study, we integrated two disparate transcriptomic and metabolomic datasets to find meaningful biomarkers and then used an independent dataset to test the sensibility and specificity of these biomarkers.
resultsBy using integrated two datasets, we discovered that the biomarkers involved in the glycolysis pathway are highly enriched, including 4 genes (ENO1, TPI1, PKG1 and LDHC) and 2 metabolites (lactate and pyruvate). The 4 genes were significantly down-regulated in OS samples as well as the 2 metabolites. The mixed metabolites + genes signature also outperformed metabolites or genes alone, with recall being 0.813 and F-measure being 0.812. And the AUC value of metabolites + genes classifier was 0.825 (compared to 0.58 for metabolites and 0.821 for genes alone).
conclusionOur findings establish that integrated transcriptomic and metabolomic signature can be used to distinguish OS malignant with good diagnostic accuracy superior to other methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.